Clinical Challenges and Consequences of Measurable Residual Disease in Non-Apl Acute Myeloid Leukemia

Cancers - Switzerland
doi 10.3390/cancers11111625
Full Text
Abstract

Available in full text

Date
Authors
Publisher

MDPI AG

Related search

Measurable Residual Disease Testing for Personalized Treatment of Acute Myeloid Leukemia

APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
ImmunologyAllergyMicrobiologyMedicineForensic MedicinePathology
2019English

How Close Are We to Incorporating Measurable Residual Disease Into Clinical Practice for Acute Myeloid Leukemia?

Haematologica
Hematology
2019English

Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context

Frontiers in Oncology
Cancer ResearchOncology
2019English

Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia

Cancer
Cancer ResearchOncology
2007English

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications.

Mediterranean Journal of Hematology and Infectious Diseases
Infectious DiseasesHematology
2016English

Pattern Associated Leukemia Immunophenotypes and Measurable Disease Detection in Acute Myeloid Leukemia or Myelodysplastic Syndrome With Mutated NPM1

Cytometry Part B - Clinical Cytometry
Forensic MedicinePathologyHistologyCell Biology
2018English

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?

Journal of Clinical Medicine
2017English

Differentiation Therapy in Acute Myelogenous Leukemia (Non-Apl)

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2000English

Immunologic Consequences of Chemotherapy for Acute Myeloid Leukemia

Journal of Pediatric Hematology/Oncology
Child HealthOncologyPediatricsHematologyPerinatology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy